Clinical trials in Meldola – page 20

439 clinical trials in Meldola, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in ItalyStudi-Clinici.it

Meldola at a glance

439

clinical trials

Paediatric trials0
Research sites1

Quick filters

439 trials in Meldola

Open in trial search

Myelofibrosis

Not recruiting

Study of RVU120 and Ruxolitinib for Patients with Intermediate or High-Risk Myelofibrosis

Registered drugNo placebo

Study of RVU120 and Ruxolitinib for Patients with Intermediate or High-Risk Myelofibrosis

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Ruxolitinib
Sponsor:Ryvu Therapeutics S.A.

Contact Research Centre

Neoplasm

Not recruiting

Study on the Safety and Tolerability of TransCon IL-2 β/γ, Pembrolizumab, and Chemotherapy in Adults with Advanced or Metastatic Solid Tumors

Registered drugNo placebo

Study on the Safety and Tolerability of TransCon IL-2 β/γ, Pembrolizumab, and Chemotherapy in Adults with Advanced or Metastatic Solid Tumors

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Acp-017
Sponsor:Ascendis Pharma Oncology Division A/S

Contact Research Centre

Acute myeloid leukaemia+1

Not recruiting

Study of RVU120 for Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

InvestigationalNo placebo

Study of RVU120 for Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:7,8-Dibromo-5,6-Dihydro-9-Methyl-2-(1-Piperazinyl)-4H-Imidazo[4,5,1-Ij]Quinoline Hydrochloride
Sponsor:Ryvu Therapeutics S.A.

Contact Research Centre

Lung adenocarcinoma

Not recruiting

Durvalumab versus standard chemotherapy drug combination in elderly patients with advanced non‑small cell lung cancer

Registered drugNo placebo

Durvalumab versus standard chemotherapy drug combination in elderly patients with advanced non‑small cell lung cancer

Registered drugNo placebo

Italy

Participants:65+ years
Substances:Carboplatin
Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Contact Research Centre

Endometrial cancer recurrent

Not recruiting

A Phase 3 Randomized Open-Label Study of Sacituzumab Govitecan Versus Physician's Choice in Recurrent or Persistent Endometrial Cancer Post-Chemotherapy and Immunotherapy

Registered drugNo placebo

A Phase 3 Randomized Open-Label Study of Sacituzumab Govitecan Versus Physician's Choice in Recurrent or Persistent Endometrial Cancer Post-Chemotherapy and Immunotherapy

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Paclitaxel
Sponsor:Gilead Sciences Inc.

Contact Research Centre

Hormone-dependent prostate cancer+1

Not recruiting

A Study of Mevrometostat and Enzalutamide for Men with Metastatic Castration-Sensitive Prostate Cancer Who Have Not Received Hormonal Therapy or Chemotherapy

Registered drug

A Study of Mevrometostat and Enzalutamide for Men with Metastatic Castration-Sensitive Prostate Cancer Who Have Not Received Hormonal Therapy or Chemotherapy

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Enzalutamide
Sponsor:Pfizer Inc.

Contact Research Centre

A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

Not recruiting

Registered drugNo placebo

A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Abemaciclib
Sponsor:AstraZeneca AB

Contact Research Centre

Malignant melanoma stage IV+1

Not recruiting

Study of BNT111 and cemiplimab in patients with advanced melanoma who have not responded to other therapies

Registered drugNo placebo

Study of BNT111 and cemiplimab in patients with advanced melanoma who have not responded to other therapies

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Cemiplimab
Sponsor:BioNTech SE

Contact Research Centre

Malignant melanoma

Not recruiting

A Study of Lifileucel with Cyclophosphamide, Fludarabine, and Aldesleukin for Adults with Previously Treated Advanced Melanoma

Registered drugNo placebo

A Study of Lifileucel with Cyclophosphamide, Fludarabine, and Aldesleukin for Adults with Previously Treated Advanced Melanoma

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Aldesleukin
Sponsor:Iovance Biotherapeutics Inc.

Contact Research Centre

Breast cancer+2

Not recruiting

A Study of Disitamab Vedotin for Adults with HER2 Expressing Advanced Breast Cancer

InvestigationalNo placebo

A Study of Disitamab Vedotin for Adults with HER2 Expressing Advanced Breast Cancer

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Disitamab Vedotin
Sponsor:Pfizer Inc.

Contact Research Centre

Breast cancer+1

Not recruiting

Long-term safety study of ribociclib with letrozole, tamoxifen, or goserelin acetate in patients with HR-positive, HER2-negative advanced or metastatic breast cancer

Registered drugNo placebo

Long-term safety study of ribociclib with letrozole, tamoxifen, or goserelin acetate in patients with HR-positive, HER2-negative advanced or metastatic breast cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Goserelin Acetate
Sponsor:Novartis Pharma AG

Contact Research Centre

Triple negative breast cancer

Not recruiting

Study of Datopotamab Deruxtecan with or without Durvalumab compared to standard treatment for patients with Stage I-III triple-negative breast cancer who have remaining cancer after initial therapy

Registered drugNo placebo

Study of Datopotamab Deruxtecan with or without Durvalumab compared to standard treatment for patients with Stage I-III triple-negative breast cancer who have remaining cancer after initial therapy

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:AstraZeneca AB

Contact Research Centre

Other cities in Italy

The busiest research cities in the country

All 234 cities in Italy

Clinical research in Meldola

What the registry says about research in the country

01 Hematologic Malignancies

Innovative research focusing on blood cancers, including studies of novel therapeutic combinations for acute myeloid leukemia, multiple myeloma, and various lymphomas.

Advanced treatments for diffuse large B-cell lymphoma
Multiple myeloma therapies for transplant-ineligible patients
Novel approaches in myelodysplastic syndrome

Studies are evaluating targeted therapies and immunotherapy combinations to improve patient outcomes.

02 Solid Tumors

Comprehensive research into advanced solid tumors, with particular emphasis on colorectal cancer, non-small cell lung cancer, and breast cancer.

Targeted therapies for metastatic colorectal cancer
Novel combinations for advanced NSCLC
Innovative approaches in metastatic breast cancer

Investigations focus on personalized treatment strategies and novel drug combinations.

03 Genitourinary Cancers

Groundbreaking studies in urological cancers, including research on prostate cancer, urothelial cancer, and renal cell carcinoma.

Advanced treatments for metastatic prostate cancer
Maintenance therapy in urothelial cancer
Immunotherapy approaches in renal cell carcinoma

Research aims to improve survival rates through innovative therapeutic strategies.

Back to Italy All countries